SCHEMBL1383343

SCHEMBL1383343

C=C(C(N)=O)c1ccc(OC)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 6/20 0.64
CA2 P00918 6/20 0.64
PARP10 Q53GL7 2/20 0.64
PARP1 P09874 1/20 0.64
PARP2 Q9UGN5 1/20 0.64
PARP4 Q9UKK3 1/20 0.64
MAPT P10636 1/20 0.58
CES2 O00748 2/20 0.57
CES1 P23141 2/20 0.57
PRSS1 P07477 1/20 0.53
PRSS2 P07478 1/20 0.53
PRSS3 P35030 1/20 0.53
PLK1 P53350 1/20 0.50
MAPK1 P28482 1/20 0.49
RAB9A P51151 1/20 0.49
HSD17B10 Q99714 1/20 0.49
ALDH1A1 P00352 1/20 0.49
GAA P10253 1/20 0.49
GSK3B P49841 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29926783 0.87 CA1 (0.48) CA1CA2PARP10PARP1PARP2
SCHEMBL5378414 0.83 MAPT (0.59) CA1CA2PARP10PARP1PARP2
SCHEMBL1450228 0.82 PARP10 (0.39) CA1CA2PARP10PARP1PARP2
SCHEMBL18982976 0.82 CES2 (0.72) CA1CA2PARP10PARP1PARP2
SCHEMBL28597822 0.82 MAPT (0.66) CA1CA2PARP10PARP1PARP2
SCHEMBL562943 0.82 CA1 (0.63) CA1CA2PARP10PARP1PARP2
SCHEMBL11351909 0.80 PDE4A (0.47) CA1CA2PARP10PARP1PARP2
SCHEMBL28547220 0.80 MAPT (0.58) CA1CA2PARP10PARP1PARP2
SCHEMBL4910445 0.80 CA1 (0.59) CA1CA2PARP10PARP1PARP2
SCHEMBL2224707 0.79 PARP10 (0.68) PARP10MAPTMAPK1RAB9AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4828407-B2 2011-11-30 JP claimed
WO-2008062424-A2 SUBSTITUTED 4,5-DIHYDRO-1H-PYRAZOLE DERIVATIVES AS CANNABINOID MODULATORS CADILA HEALTHCARE LIMITED (IN) 2008-05-29 WO claimed
CN-1234785-C Liquid ink containing surface treatment coloring agent particle and productive method thereof SAMSUNG ELECTRONICS CO LTD (KR) 2006-01-04 CN claimed
EP-1594869-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF Targacept, Inc. (US) 2005-11-16 EP claimed
WO-2004076449-A2 3-SUBSTITUTED-2(ARYLALKYL)-1-AZABICYCLOALKANES AND METHODS OF USE THEREOF TARGACEPT, INC. (US) 2004-09-10 WO claimed
CN-1358807-A Liquid ink containing surface treatment coloring agent particle and productive method thereof SAMSUNG ELECTRONICS CO LTD (KR) 2002-07-17 CN claimed
CN-87101979-A diphenylmethane derivatives and pharmaceutical use 1987-10-28 CN claimed
WO-2026047630-A1 HETEROCYCLIC COMPOUNDS AS EGFR INHIBITORS HETERO LABS LIMITED (IN) 2026-03-05 WO disclosed
US-20250057850-A1 ERBB/BTK INHIBITORS DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-02-20 US disclosed
CN-111747950-B Pyrimidine derivatives for the treatment of cancer 深圳福沃药业有限公司 2024-01-23 CN disclosed
CN-111875585-B Kinase inhibitors 上海艾力斯医药科技股份有限公司 2023-06-23 CN disclosed
CN-111686110-B Compounds and compositions for modulating EGFR mutant kinase activity 株式会社柳韩洋行 2023-06-16 CN disclosed
CN-115322131-A Synthesis method of beta-fluoroindole acrylamide compound 温州大学 2022-11-11 CN disclosed
CN-101138036-A Improved disks for data storage MEMPILE INC (US) 2008-03-05 CN disclosed
CN-1234785-C Liquid ink containing surface treatment coloring agent particle and productive method thereof SAMSUNG ELECTRONICS CO LTD (KR) 2006-01-04 CN disclosed
CN-1358807-A Liquid ink containing surface treatment coloring agent particle and productive method thereof SAMSUNG ELECTRONICS CO LTD (KR) 2002-07-17 CN disclosed
CN-1014889-B Method for producing stilbene derivative EISAI CO LTD (JP) 1991-11-27 CN disclosed
CN-87101979-A diphenylmethane derivatives and pharmaceutical use 1987-10-28 CN disclosed
EP-0001997-B1 ELECTRON BEAM-CURABLE PHOTORESIST LACQUERS BAYER AG (DE) 1981-02-11 EP disclosed
EP-0001997-A1 Electron beam-curable photoresist lacquers BAYER AG (DE) 1979-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250057850-A1 ERBB/BTK INHIBITORS ERBB2, BTK, ERBB3 CA1 4026/4885CA2 1603/4885PARP10 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.